[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-blood-pressure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-blood-pressure":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,39,70,94,125,171,201,231,255,285,309,347,369,395,420,445,468,491,514,540,565,594],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100498094","diagnosing-variable-primary-aldosteronism-100498094",false,"NCT05765786","Diagnosing Variable Primary Aldosteronism.","Do we Miss a Common Subset of Primary Aldosteronism in Which There is Cyclical or Exaggerated Diurnal Variation in Secretion?","Inclusion Criteria:\n\n* People with clinically suspected PA but have not met criteria for diagnosis. Suspicion based on low-renin (renin activity \\\u003C0.5 nmol\u002Fh\u002FL or renin mass \\\u003C5 ng\u002FL), plasma sodium \\> 140mmol\u002FL or plasma potassium \\\u003C 4mmol\u002FL.\n* Patients who have been diagnosed with PA and had previous aldosterone samples \\\u003C277 pmol\u002FL, a level which would normally not qualify for confirmatory testing.\n* Patients with aldosterone results done at different times that indicate variability in production.\n* Willing to consent and participate in the study.\n\nExclusion Criteria:\n\n* Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks.\n* People on end of life treatment.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with Primary Aldosteronism.",[24,25],"Primary Aldosteronism","High Blood Pressure","RECRUITING","2026-06-12",{"date":29,"type":30},"2026-06-15","ACTUAL",{"date":32,"type":30},"2023-02-24",{"date":34,"type":20},"2027-07-24",{"name":36,"class":37},"Queen Mary University of London","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100639675","phase-2-effect-of-an-isolevuglandin-scavenger-on-salt-sensitivity-of-blood-pressure-and-immune-cell-activation-in-humans-100639675","NCT07602166","Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans","Inclusion Criteria:\n\n* We will perform analyses in participants previously phenotyped for SSBP, defined as a change in systolic blood pressure ≥10 mmHg from salt-loading to salt-depletion,\n* Over 18 years of age. Able to give informed consent,\n\nExclusion criteria:\n\n* Salt-resistant people,\n* Acute cardiovascular event(s) within the previous 6 months,\n* inability to understand the nature, scope, and possible consequences of the study or to participate in\u002Fcomply with the protocol,\n* Current excessive alcohol or illicit drug use,\n* BP below the inclusion criteria levels after discontinuation of therapy,\n* Concomitant diabetes mellitus, type I or II,\n* Autoimmune disease,\n* Recent vaccination,\n* Younger or older than inclusion criteria,\n* Pregnant or breastfeeding\n* Women of childbearing potential unwilling to use highly effective contraceptive (see Risk section),\n* Confirmed or suspected renal, renovascular or endocrine causes of secondary hypertension,\n* Treatment with agents known to increase BP (e.g., adrenergic agonists for ADHD, SSRI and SNRI antidepressants, chronic use of decongestants or non-steroidal anti-inflammatory drugs,\n* Active or ongoing infection, including HIV\u002FAIDS,\n* Active or ongoing malignancy with the exception of basal cell carcinoma of the skin,\n* Severe psychiatric disorders,\n* Any condition that may alter the immunological results of the study including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, giant cell arteritis, psoriasis, inflammatory bowel disease, and multiple sclerosis,\n* Use of glucocorticoids, immunosuppressants, direct immunomodulators or chemotherapeutic drugs that in the judgment of the investigators may include a major inflammatory component,\n* Individuals who have contraindications to high salt diets (e.g. heart, renal, or liver failure) or low salt diets (e.g. postural orthostatic tachycardia syndrome, prescribed salt tablets, fludrocortisone or midodrine) or 24-hr ambulatory blood pressure monitoring (e.g. women with bilateral upper extremity lymphedema following breast cancer surgeries),\n* Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: AST or ALT \\>1.5x the upper limit of normal or total bilirubin ≥1.5 mg\u002Fdl,\n* Use of Aspirin,\n* Use of monoamine oxidase inhibitors (MAO-I),\n* Individuals with medical contraindications to certain food content,\n* Use of nitrate therapy. (Participants who are taking PDE-5 inhibitors will be instructed to discontinue use at least 48 hours prior to testing),\n* Patients with resistant hypertension, defined as above-goal blood pressure despite the concurrent use of three antihypertensive drug classes at screening, will be excluded for safety reasons,\n* Average of three office-based blood pressure readings greater than 160 mmHg systolic or 100 mmHg diastolic will not be eligible for enrollment,\n* Use of drugs such as anticoagulants (e.g., warfarin), beta-blockers, antiarrhythmics, antidepressants\u002Fantipsychotics, and other medications primarily metabolized by CYP2C9, CYP2C19, and CYP2D6 that may cause drug-drug interaction.",{"count":46,"type":20},20,"INTERVENTIONAL",[49],"PHASE2","Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+).\n\nThis trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks.\n\nThis phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.",[52,25,53,54],"Salt Sensitivity of Blood Pressure","Inflammation","Renin-Angiotensin-Aldosterone System",[56,57,58,59],"salt sensitivity","hypertension","renin-angiotensin-aldosterone system","immune cells","NOT_YET_RECRUITING","2026-05-20",{"date":63,"type":30},"2026-05-26",{"date":65,"type":20},"2026-07",{"date":67,"type":20},"2031-07",{"name":69,"class":37},"Vanderbilt University Medical Center",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":38},"100613536","oura-blood-pressure-profile-study-100613536","NCT07267871","Oura Blood Pressure Profile Study","Oura Blood Pressure Profile Study: An Evaluation of the Oura Blood Pressure Profile Algorithm for Identifying Signs of Hypertension","Inclusion Criteria\n\n* Located in United States\n* Aged 22 years or older at time of eligibility screener\n* Oura Ring user (Oura Ring Gen3 or newer)\n* User of the English version of the Oura App\n* Smartphone (iOS or Android) user\n* Able to provide consent electronically\n\nExclusion Criteria\n\n* User of implanted cardiac electronic device(s)\n* Currently pregnant\n* Within 12 weeks postpartum",true,"22 Years",{"count":80,"type":20},2000000,"The proposed study is designed as a prospective, single-arm, observational, non-significant risk device study to evaluate the performance of Oura's investigational Blood Pressure Profile algorithm in identifying signs of hypertension.",[83,25],"Hypertension","2026-04-09",{"date":86,"type":30},"2026-04-13",{"date":88,"type":30},"2025-12-17",{"date":90,"type":20},"2027-05",{"name":92,"class":93},"Ouraring Inc.","INDUSTRY",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":47,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100631901","digital-education-for-hypertension-management-effects-on-self-care-and-health-literacy-100631901","NCT07506707","Digital Education for Hypertension Management: Effects on Self-Care and Health Literacy","Digital Education Approach in Hypertension Management: Its Effect on Self-Care Behaviors and Health Literacy","DIGIHYPE-HTN","Inclusion Criteria:\n\n* Adults aged 50 years or older\n* Individuals with a clinical diagnosis of hypertension or those regularly using antihypertensive medication\n* Individuals actively registered at the Life Center and receiving regular services\n* Participants who provide written and verbal informed consent to voluntarily join the study\n* Individuals able to fully participate in the designated digital health education sessions\n* Participants capable of maintaining consistency throughout the intervention and follow up periods\n\nExclusion Criteria:\n\n* Individuals without a diagnosis of hypertension\n* Individuals unable to complete questionnaires or education sessions due to communication barriers or cognitive limitations\n* Illiterate individuals, as data collection requires reading and completing written questionnaires\n* Individuals unable to maintain participation or adhere to the follow up schedule during the study period","50 Years","80 Years",{"count":105,"type":20},166,[107],"NA","The goal of this clinical trial is to learn whether a digital education program can help people with high blood pressure (hypertension) manage their condition better. The program aims to improve self-care behaviors and health literacy by teaching participants how to use digital tools, follow healthy lifestyle habits, and take their medicines regularly.\n\nResearchers will compare two groups. One group will receive digital education that includes short videos, brochures, and podcasts about blood pressure control and how to use online health platforms such as e-Nabız (Turkey's national e-health system). The other group will not receive this education. Participants will attend two sessions during two weeks.\n\nThe main questions are:\n\nDoes digital education improve self-care and e-health literacy in people with hypertension? Does it help participants take their medicine as prescribed and maintain healthy habits such as diet and exercise?",[83,25],[83,111,112,113,114,115],"Digital education","Self-care behaviors","Health literacy","e-Health literacy","Medication adherence","2026-04-03",{"date":118,"type":30},"2026-04-08",{"date":120,"type":20},"2026-04-11",{"date":122,"type":20},"2026-05-30",{"name":124,"class":37},"Bartın Unıversity",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":47,"phases":136,"briefSummary":137,"conditions":138,"keywords":153,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":38},"100572617","wild-blueberries-for-gut-brain-and-heart-health-in-adults-with-high-blood-pressure-100572617","NCT06735599","Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure","Effects of Wild Blueberry Consumption on Gut, Brain, and Cardiovascular Health in Non-Hispanic Black and White Adults With High Blood Pressure","Inclusion Criteria:\n\n* Individuals 45-65 years of age\n* Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and\u002For diastolic blood pressure = 80-89 mmHg) for at least 6 months\n* BMI 25-35 kg\u002Fm2 via anthropometric measurements.\n* Ability to give consent\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of one hypertensive drug for less than three months\n* Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury\n* Smoking\n* Alcohol consumption (\\>2 drinks\u002Fday)\n* Consuming antioxidant, probiotic, and prebiotic supplements\n* Pregnant or lactating\n* Participating in a weight loss program","45 Years","65 Years",{"count":135,"type":20},40,[107],"The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.",[139,25,140,141,142,143,144,145,146,147,148,149,150,151,53,152],"Hypertension (Without Type 2 Diabetes Mellitus)","Male","Female","Adult","Cognition","Endothelial Function (Reactive Hyperemia)","Oxidative Stress","Diet","Overweight","Body Composition Measurement","Gut Microbiome","Arterial Stiffness","Caucasian Whites","Microvascular Function",[154,83,147,25,155,156,157,158,159,160,161],"Blueberries","Endothelial Function","Cognitive Function","Dietary intervention","functional foods","gut microbiota","arterial stiffness","microvascular function","2026-03-23",{"date":164,"type":30},"2026-03-27",{"date":166,"type":30},"2024-09-17",{"date":168,"type":20},"2027-01-01",{"name":170,"class":37},"Georgia State University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":47,"phases":181,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":38},"100558766","phase-1-understanding-the-health-effect-of-a-bioactive-peptide-from-egg-a-pilot-study-100558766","NCT06555393","Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study","A Preliminary Human Study on Bioavailability and Efficacy of Bioactive Peptide IRW in Egg White Hydrolysate","Inclusion Criteria:\n\nHealthy control group:\n\n* Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area\u002Fdriving distance).\n* Normal weight (BMI below 25 kg\u002Fm2 or Asian population below 23 kg\u002Fm2 )\n* Waist circumference below the following ethnic specific cut offs: Canada \u002F USA: \\\u003C102 cm men and \\\u003C88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: \\\u003C94 cm men and \\\u003C80 cm women; Asians, Japanese, South and Central Americans: \\\u003C90 cm men and \\\u003C80 cm women\n* Fasting glucose \\\u003C5.6 mmol\u002FL\n* HbA1c \\\u003C5.6 %\n* Blood pressure \\\u003C130\u002F85 mmHg\n* Triglycerides \\\u003C1.7 mmol\u002FL\n* HDL-Cholesterol \\>1.03 mmol\u002FL men and \\>1.29 mmol\u002FL women\n* Body weight stable (within 3% fluctuation) for at least 6 months prior to the study\n* Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)\n\nIndividuals at risk of diabetes\u002Fhaving type 2 diabetes:\n\n* Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area\u002Fdriving distance).\n* Overweight or obesity (BMI above 25 kg\u002Fm2 or Asian population above 23 kg\u002Fm2)\n* Waist circumference at or above the following ethnic specific cut offs: Canada \u002F USA: ≥ 102 cm men and ≥ 88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: ≥ 94 cm men and ≥ 80 cm women; Asians, Japanese, South and Central Americans: ≥ 90 cm men and ≥ 80 cm women\n* Fasting glucose ≥ 6.0 mmol\u002FL\n* HbA1c ≥ 6.0 %\n* Body weight stable (within 3% fluctuation) for at least 6 months prior to the study\n* Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)\n\nExclusion Criteria:\n\n* Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia, with endocrine disorders other than T2D\n* Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines, and omega-3 supplements)\n* Pregnant\u002Flactating women\n* Individuals aged above 70 years\n* Smokers (current smokers: daily\u002Foccasional and those who have smoked more than 100 cigarettes in their life)\n* Individuals with specific nutritional restrictions (e.g. vegetarianism excluding eggs from their diet, vegan or with egg allergy) will be excluded\n* Individuals with poorly controlled (HbA1c \\>12.0%) diabetes or taking exogenous insulin will be excluded. Other anti-diabetic and lipid-lowering medications will be documented.","70 Years",{"count":180,"type":20},28,[182],"PHASE1","Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure.\n\nParticipants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week.\n\nParticipants in the healthy control group will undergo 1 treatment only (one day).",[185,25,186],"High Blood Sugar","Overweight and Obesity",[188,189,190,191],"high blood pressure","high blood sugar","overweight","obesity","2026-03-12",{"date":194,"type":30},"2026-03-13",{"date":196,"type":30},"2026-02-25",{"date":198,"type":20},"2026-10",{"name":200,"class":37},"University of Alberta",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":47,"phases":211,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":38},"100628262","can-changes-in-dialysate-sodium-concentration-improve-blood-pressure-and-endothelial-function-in-chronic-hd-patients-100628262","NCT07459348","Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Chronic HD Patients?","Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Patients Undergoing Chronic Hemodialysis?","NADI","Inclusion Criteria:\n\n* Adults receiving chronic in-center hemodialysis at Regional Hospital Gødstrup\n* Age ≥ 18 years\n* On thrice-weekly hemodialysis for a stable period (as assessed in EPJ)\n* Plasma sodium within the range required for safe participation (as per screening)\n* Able to understand study information and provide written informed consent\n* Eligible based on review of electronic patient record (dialysis duration, frequency, age, p-sodium)\n\nExclusion Criteria:\n\n* Significant cardiac disease that may interfere with participation, including:\n* Heart failure (with clinically relevant instability)\n* Recent acute myocardial infarction (date verified in EPJ)\n* Pacemaker (specific types that interfere with measurements)\n* History of stroke or TCI (date verified in EPJ)\n* Amputation of an extremity (affects body composition measurements)\n* Diabetes with unstable glycemic control or recent major treatment changes\n* Any condition that prevents accurate blood pressure measurement or CO-rebreathing\n* Inability to complete study procedures (questionnaires, monitoring, blood sampling)\n* Expected inability to complete both intervention periods (e.g., planned transfer, transplantation)\n* Declines participation after receiving oral and written information",{"count":210,"type":20},25,[107],"People with end stage kidney disease cannot regulate salt and water normally, which often leads to high blood pressure, fluid overload, and a higher risk of heart disease.\n\nHemodialysis is a life sustaining treatment that removes waste products, excess fluid, and electrolytes from the blood. However, the treatment itself can influence blood pressure and how the blood vessels function. Many patients experience symptoms such as thirst, headaches, fatigue, and swelling, which affect both daily well being and long term health. One possible way to reduce these problems may be as simple as adjusting the amount of sodium in the dialysis fluid.\n\nDuring dialysis, substances move between the patient's blood and the dialysate, the special fluid used in the machine. Sodium is one of the most important components because it helps regulate fluid balance and blood pressure. A higher sodium concentration in the dialysate can make patients feel more thirsty, cause them to drink more, and lead to fluid retention and higher blood pressure. On the other hand, lowering sodium too much can cause dizziness, low blood pressure, cramps, and discomfort during treatment. Because of this, there is ongoing debate about what the \"right\" sodium level should be.\n\nToo much sodium over time may also harm the blood vessels. The inner lining of the vessels, called the endothelium, is protected by a thin layer known as the glycocalyx. This layer helps prevent sodium from entering the vessel wall and supports the production of nitric oxide, a molecule that relaxes blood vessels and reduces inflammation. High salt exposure can damage the glycocalyx and reduce nitric oxide production, making the vessels stiffer and raising blood pressure. In dialysis patients, low nitric oxide levels are linked to worse outcomes and episodes of rising blood pressure during treatment. Some small studies suggest that lowering dialysate sodium can improve blood pressure and endothelial function, but larger studies have not shown clear effects on survival. This indicates that we still do not fully understand which patients benefit most or how sodium changes affect both physical and subjective symptoms.\n\nThis study aims to fill these knowledge gaps by examining how a lower sodium concentration in the dialysate affects blood pressure, blood vessel function, fluid overload, inflammation, and patient reported symptoms. The goal is to provide new insights that could help tailor dialysis treatment to individual patients in a simple and cost effective way.\n\nThe study will compare two sodium concentrations: a lower level (133 mmol\u002FL) and the standard level used in many clinics (139 mmol\u002FL). Twenty five patients receiving chronic in center hemodialysis will participate. Each patient will undergo both treatments for three weeks each, in random order, with a two week washout period in between. This crossover design allows each patient to serve as their own control, making it easier to detect meaningful differences.\n\nThe main outcome is the difference in 24 hour systolic blood pressure between the two sodium levels. Secondary outcomes include changes in nitric oxide levels in the blood, measures of fluid overload using two different techniques, markers of inflammation, arterial stiffness, and patient reported symptoms such as thirst, fatigue, and overall well being. The study will also compare two methods for assessing fluid overload: bioimpedance spectroscopy and a newer carbon monoxide rebreathing technique.\n\nBlood pressure and arterial stiffness will be measured over 44 hours using a portable device. Blood samples will be collected to analyze nitric oxide, inflammatory markers, and sodium handling in red blood cells. Fluid status will be measured using both bioimpedance and the CO rebreathing method. Patients will complete a weekly questionnaire developed together with dialysis patients to capture their experiences and symptoms.",[214,215,216,25],"Dialysis Dependent Chronic Kidney Disease","Dialysis Patients","Sodium Excess",[218,219,220,221,222],"Dialysate Sodium Concentration","Hemodialysis","Blood Pressure Control","Endothelial Function \u002F Nitric Oxide (NOx)","Fluid Overload Assessment (CO Rebreathing & Bioimpedance)","2026-03-11",{"date":194,"type":30},{"date":226,"type":20},"2026-05-01",{"date":228,"type":20},"2029-12-31",{"name":230,"class":37},"Gødstrup Hospital",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":77,"sex":237,"minAge":17,"maxAge":132,"enrollmentInfo":238,"targetDuration":4,"studyType":47,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":38},"100625271","cardiometabolic-risk-in-pregnancy-and-postpartum-100625271","NCT07420465","Cardiometabolic Risk in Pregnancy and Postpartum","Inclusion Criteria:\n\n* Singleton pregnancy\n* 18 years and older\n* 3rd trimester of pregnancy at enrollment\n* Will be living in the area for the study duration\n* Women with or without pregnancy complications (e.g., gestational hypertension, preeclampsia, gestational diabetes)\n\nExclusion Criteria:\n\n* Multiple births\n* Diagnosed CVD or diabetes prior to pregnancy\n* Renal or other serious maternal diseases pre-pregnancy","FEMALE",{"count":239,"type":20},200,[107],"The goal of this study is to evaluate changes in blood pressure and early cardiovascular risk markers and to determine whether a postpartum education intervention can improve cardiovascular risk monitoring among pregnant women in their third trimester through six months postpartum in Accra, Ghana. The study includes women aged 18 years and older with and without pregnancy-related cardiometabolic complications. Findings from this study will inform the development of scalable postpartum screening and intervention strategies to reduce long-term cardiovascular disease risk among women.",[243,244,245,25],"Hypertensive Disorders of Pregnancy","Postpartum Hypertension","Cardiovascular Disease Risk","2026-02-11",{"date":248,"type":30},"2026-02-19",{"date":250,"type":20},"2026-02",{"date":252,"type":20},"2027-12",{"name":254,"class":37},"Forgive Avorgbedor",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":263,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":47,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":284},"100623573","blood-pressure-care-for-advancing-real-world-evidence-bpcare-100623573","NCT07398391","Blood Pressure Care for Advancing Real-World Evidence (BPCARE)","Blood Pressure Care for Advancing Real-World Evidence (BPCARE): an RCT of Adherence","BPCARE","Inclusion Criteria:\n\n* Have a clinical diagnosis of hypertension determined at screening,\n* Be at least 21 years of age,\n* English as a second language,\n* Be able to provide written informed consent and participate in study procedures,\n* Have a last least one recorded automated clinic systolic BP reading of at least 130 mmHg within the past year OR at least one home SBP reading of ≥140 mmHg in the last year. AND\u002FOR answer is in range of less than two months to \"when was the last time you missed a dose of your hypertension medication?\"\n* Will not move out of San Diego in the next 6 months, and\n* Have access to a mobile phone or computer with video telecommunication capacity (e.g. Zoom)\n\nExclusion Criteria:\n\n* A cardiovascular event or hospitalization for unstable angina within last 3 months,\n* Symptomatic heart failure within the past 6 months or left ventricular ejection fraction \\\u003C 35%,\n* Individuals who are pregnant, planning on becoming pregnant within the next 7 months\n* Current participation in another clinical trial that includes taking medications that may change blood pressure, or\n* Major factors judged to be likely to significantly limit comprehension of or adherence to interventions including dementia, psychotic disorders, or affect ability to conduct pill counts\n* Any immediate family members participating in the trial.","21 Years",{"count":265,"type":20},250,[107],"The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications.\n\nThe main questions it aims to answer are:\n\n1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care?\n2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care?\n\nResearchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence.\n\nParticipants will:\n\n* Be randomly assigned to either the BPCARE intervention or enhanced usual care\n* Receive hypertension education and a home blood pressure monitor\n* Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only)\n* Complete questionnaires assessing medication adherence and related psychosocial factors\n* Have blood pressure monitored using connected home blood pressure devices\n* Complete pill counts to assess medication adherence over a nine-month follow-up period",[83,25],[270,271,272,273,274],"Medication Adherence","Chronic Disease Management","Blood Pressure Self-Management","Federally Qualified Health Center","Motivational Interviewing","2026-02-04",{"date":277,"type":30},"2026-02-09",{"date":279,"type":30},"2026-01-09",{"date":281,"type":20},"2030-05",{"name":283,"class":37},"University of California, San Diego",2,{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":237,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":47,"phases":295,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":38},"100481599","phase-3-safest-choice-of-antihypertensive-regimen-for-postpartum-hypertension-100481599","NCT05551104","Safest Choice of Antihypertensive Regimen for Postpartum Hypertension","Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)","SCARPH","Inclusion Criteria:\n\n* Female\n* Women who develop postpartum hypertension\\* after delivery of the placenta or chronic hypertensive postpartum women who require medication for blood pressure control.\n\n  * Postpartum hypertension requiring treatment are defined as systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than or equal to 90mmHg on at least 2 occasions at least 4 hours apart, or systolic blood pressure greater than or equal to 160mmHg or diastolic blood pressure greater than 110mmHg sustained for more than 15 minutes.\n\nExclusion Criteria:\n\n* History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema\n* Contraindication to either Nifedipine or Labetalol\n* HR \\\u003C60 or \\>110\n* Native language other than English or Spanish",{"count":294,"type":20},500,[296],"PHASE3","The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.",[299,300,25],"Postpartum Complication","Maternal Hypertension",[244],"2026-02-02",{"date":275,"type":30},{"date":305,"type":30},"2023-05-08",{"date":252,"type":20},{"name":308,"class":37},"Loma Linda University",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":47,"phases":319,"briefSummary":320,"conditions":321,"keywords":329,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":38},"100622407","effect-of-electrical-stimulation-and-exercise-on-blood-flow-in-patients-with-resistant-high-blood-pressure-100622407","NCT07383220","Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure","Effect of Combined Transcutaneous Electrical Stimulation and Isometric Exercise on Peripheral Hemodynamic Parameters in Patients With Resistant Hypertension","Inclusion Criteria:\n\n* Age between 50 and 60 years. Both sexes were included Patients had been diagnosed with hypertension for at least 5 years.\n\nPatients had resistant hypertension according to (Whelton et al 2018), defined as:\n\n* Systolic blood pressure (SBP) ≥140 mmHg and\u002For diastolic blood pressure (DBP) ≥90 mmHg despite the use of three or more antihypertensive medications of different classes, including a diuretic,\n* or controlled blood pressure (\\\u003C140\u002F90 mmHg) while on four or more antihypertensive medications.\n\nBody Mass Index (BMI) 25: 34.9 kg\u002Fm²\n\nIncreased waist circumference, defined as:\n\n* Greater than 102 cm for males.\n* Greater than 88 cm for females.\n\nExclusion Criteria:\n\n* Secondary hypertension due to identifiable causes (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma).\n* History of major cardiovascular events in the last 6 months (e.g., myocardial infarction, stroke, or heart failure exacerbation).\n* Severe musculoskeletal or neurological disorders that impair the ability to perform isometric exercise safely (e.g., recent joint replacement, severe osteoarthritis, stroke with residual motor deficit).\n* Contraindications to the use of Transcutaneous Electrical Nerve Stimulation (TENS):\n\nImplanted electronic devices: pacemakers, cardioverter defibrillators. Uncontrolled arrhythmias. Sever skin condition: open wounds, rashes, burns, eczema. Peripheral neuropathy or sensory loss.\n\n-Known cognitive impairment or psychiatric conditions that would limit the ability to follow instructions or provide informed consent.","60 Years",{"count":318,"type":20},50,[107],"The goal of this clinical trial is to learn if the combination between transcutaneous electrical nerve stimulation (TENS) and isometric exercise (IE) can improve blood pressure in men and women between 50 to 60 years old suffered from resistant hypertension which is a type of hypertension where blood pressure remains above your target goal despite the use of three or more different classes of antihypertensive medications at their maximum tolerated doses. The main question to answer is:\n\nIs there a significant effect on the combined use of TENS and IE on peripheral hemodynamic parameters in patients with resistant hypertension? Total sample will be 50 patients from both sexes\n\nI will compare between two groups:\n\nExperimental group (15 men, 10 women) will take: medication plus IE and TENS Control group (15 men, 10 women) will take: medication plus Conventional Physical Therapy Program",[322,323,324,325,326,327,328,25],"Resistant Hypertension","Hemodynamic Instability","Essential (Primary) Hypertension","Abdominal Obesity","Metabolic Syndrome","Hypertension (HTN)","Vascular Resistance",[330,331,332,333,334,335,336,337],"Mean Arterial Pressure","Peripheral Hemodynamics","Physical Therapy","Long Term Hypertension","Resistant HTN","Systolic Blood Pressure (SBP)","Diastolic Blood Pressure (DBP)","Heart Rate Variability (HRV)","2026-01-28",{"date":340,"type":30},"2026-02-03",{"date":342,"type":20},"2026-01-15",{"date":344,"type":20},"2026-06-10",{"name":346,"class":37},"Mohamed Mohamed Ali Morgan",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":178,"enrollmentInfo":355,"targetDuration":4,"studyType":47,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":364,"leadSponsor":366,"locationsCount":368},"100591912","addressing-hypertension-care-in-africa-program-100591912","NCT06986590","Addressing Hypertension Care in Africa Program","Addressing Hypertension Care in Africa (ADHINCRA) Program","ADHINCRA","Inclusion Criteria:\n\n* Aged 18 -70 years.\n* Diagnosis of hypertension and elevated systolic blood pressure measure (≥140 mmHg) on the most recent clinic visit without a diabetes diagnosis.\n* Hypertension treatment naive or on monotherapy.\n* Receives primary care at one of the participating sites.\n* Willing and able to provide informed consent in English, Twi, Dagbani, Ewe, Hausa, or Yoruba.\n* Owns a smartphone (Android or iOS).\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>70 years.\n* Severely elevated BP (≥180\u002F110mmHg).\n* Diagnosis of stroke, coronary artery disease, or kidney disease.\n* Diagnosis of end-stage renal disease (ESRD) treated with dialysis.\n* Serious medical condition which either limits life expectancy or requires active management (e.g., cancer).\n* Cognitive impairment or other conditions preventing study participation\n* Pregnant or currently nursing a child\n* Unwilling to provide informed consent",{"count":356,"type":20},800,[107],"The ADHINCRA Program is a bundle of multilevel evidence-based interventions that address multiple predictors of controlled hypertension, including patient-, provider-, and health system-level factors. The successful implementation of the ADHINCRA program will provide a rigorous and scalable model for improving hypertension control in Africa, which would ultimately reduce the risk of cardiovascular disease, stroke and kidney disease.",[83,25],"2026-01-13",{"date":362,"type":30},"2026-01-14",{"date":279,"type":30},{"date":365,"type":20},"2028-09",{"name":367,"class":37},"Johns Hopkins University",17,{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":47,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":284},"100618375","study-of-the-double-polymorphism-thr-555ile-and-glu568pro-of-the-corin-gene-as-a-risk-factor-for-arterial-hypertension-in-a-population-of-african-descent-in-guadeloupe-100618375","NCT07330804","STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE","HTAG-CORIN","Inclusion Criteria:\n\nCase inclusion criteria\n\n* Persons affiliated with or benefiting from a social security plan;\n* Over 18 years of age;\n* Considering themselves to be of Afro-Caribbean descent;\n* Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research);\n* Treated for hypertension or presenting with hypertension according to recommendations: elevated blood pressure (BP), including systolic blood pressure (SBP) ≥140 mmHg and\u002For diastolic blood pressure (DBP) ≥ 90 mmHg measured in the physician's office and confirmed over several visits on the day of inclusion or diagnosis made by ABPM or self-measurement.\n\nControl inclusion criteria:\n\n* Individuals affiliated with or benefiting from a social security plan;\n* Over 18 years of age;\n* Patients who consider themselves of Afro-Caribbean origin, of the same sex as the cases and ± 5 years of age, not treated for hypertension and not presenting with hypertension according to the HAS recommendations on the day of the inclusion visit. Controls will be recruited by the same GPs who included a person with hypertension, consulting for any other symptom\n* Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research);\n\nExclusion Criteria:\n\n* Minors; Pregnant or breastfeeding women; Protected persons, or persons under court protection; Refusal to participate. Patients unable to come to the laboratory",{"count":377,"type":20},370,[107],"Cardiovascular disease (CVD) mortality is the leading cause of death in high-income countries (particularly the United States), accounting for 23.1% of all deaths It has been established over several decades that hypertension disproportionately affects African Americans, compared with Americans of European descent:Hypertension occurs more often, at an earlier age , with greater severity , and is associated with an approximately 3-fold higher probability of death .There is also poorer control of hypertension despit e similar treatment In African Americans, CVD morbidity and mortality are compounded by the higher prevalence of T2DM, obesity, CKD, stroke, and heart failure . Despite advances in the identification of risk factors and the availability of effective treatment in hypertension, CVD disparities, persist among African Americans and are expected to increase in the future, particularly in younger age groups. Although various environmental and social factors certainly contribute to these disparities, a genetic basis, involving numerous \"candidate\" genes, is most often asserted in the literature . One of these is the Corin gene (Pan et al, 2002) which codes for the Corin protein.The latter plays a pivotal role in cardiometabolic pathophysiology through its role in the activation of natriuretic peptides .Natriuretic peptides (ANP and BNP) have a major role in the regulation of blood pressure through their vasodilatory and diuretic action. They have a lusotropic action, inhibit the renin angiotensin system, and are involved in energy metabolism (increased lipolysis and insulin secretion). They also have an anti-fibrotic, anti-proliferative, anti-inflammatory and anti-thrombotic action.The Corin gene of 244109pb has many variants that produce an inefficient protein with the corollary of the appearance of metabolic and cardiovascular pathologies in the first rank of which the HTA, the cardiac insufficiency and the renal insufficiency .Recently, a double polymorphism of the Corin gene consisting of 2 SNPs (single nucleotide polymorphisms) on the same allele of the Corin gene (I555\u002FP568) has been reported. This allele is present in the heterozygous state in 12% of African Americans but is extremely rare in Americans of European descent (\\\u003C0.5%).This double polymorphism (I555\u002FP568) has been shown to be responsible for an approximately 70% reduction in the ability of the mutated Corin protein to convert proANP or proBNP to the active form. In addition, the I555(P568) allele of Corin protein is associated with an increased risk of hypertension and concentric cardiac hypertrophy The corin allele (I555\u002FP568) is reported to be associated with poorer response to validated heart failure therapy and a higher risk of death or hospitalization for heart failure .\n\nIn Guadeloupe, where the population is predominantly of African descent.Cardiovascular disease is the leading cause of mortality.The prevalence of hypertension is 39% and more than 50% after 50 years of age . It has increased by 10% in 10 years in Guadeloupe. In France, where the prevalence of hypertension is 31%, it has increased by only 5% over the same period.\n\nHeart failure is the main cause of admission to the cardiological emergency room of the University Hospital (49%) with a mortality of 37% at 6 months. Hypertension is the first risk factor associated with heart failure (80%).To date, there are no studies on corin gene polymorphisms in Guadeloupe. Following the example of work already done in the African American population, we propose to study the role of the double polymorphism (I555\u002FP568) in the determinism of hypertension in the population of African descent in Guadeloupe.",[25],[382,383,384,385,386],"double polymorphisme","Corin","natriuretic peptide","biomarker","Afro Caribbean","2026-01-05",{"date":279,"type":30},{"date":390,"type":30},"2025-01-16",{"date":392,"type":20},"2026-08",{"name":394,"class":37},"Centre Hospitalier Universitaire de la Guadeloupe",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":77,"sex":16,"minAge":402,"maxAge":17,"enrollmentInfo":403,"targetDuration":4,"studyType":47,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":38},"100481710","home-bp-monitoring-100481710","NCT05552547","Home BP Monitoring","Home BP Monitoring for Diagnosis of Hypertension in African American Adolescents","Inclusion Criteria:\n\n* Self-identify or identified by a parent as African-American or of partly African American ancestry\n\nExclusion Criteria:\n\n* Prior hypertension diagnosis\n* Prescribed BP medication\n* History of congenital heart disease\n* History of solid organ transplant\n* Prescribed and using stimulants and other medications on a regular basis known to raise blood pressure such as testosterone and nicotine replacement","13 Years",{"count":404,"type":20},750,[107],"Most cases of high blood pressure in teens are missed for a number of reasons. One reason is that the most common way to make a diagnosis is to make three or more blood pressure measurements in a doctor's office on separate days. This can be inconvenient. Also, measuring blood pressure in the office might be inaccurate, since children (including teens) might have high values in the office but normal values at home. For these reasons, investigators wish to study a different way to identify teens with high blood pressure. Home BP measurements have been used in Europe to make a diagnosis, but not yet in the United States, and never in a higher risk population of teens. African American teens are at higher risk for high blood pressure than other teens. Investigators will compare the values received from the home BP machines to another method (24 hour ambulatory BP monitoring or ABPM) which is the best standard for diagnosis. Investigators also want to learn more about participants experience and their child's experience with both methods. A small sample of participating teens and parents will be invited to participate in short telephone interviews. This study plans to enroll a total of 750 teens at UH. Recruitment will not take place from other organizations.",[25],[409,410],"African American Teen","Home blood pressure monitoring","2025-12-02",{"date":413,"type":30},"2025-12-10",{"date":415,"type":30},"2023-10-01",{"date":417,"type":20},"2026-09-30",{"name":419,"class":37},"University Hospitals Cleveland Medical Center",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":47,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":38},"100612911","rapid-management-of-resistant-hypertension-in-the-public-health-system-fast-control-100612911","NCT07259733","Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)","FastControl","Inclusion Criteria: Age between 18 and 75 years;\n\nTreatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB);\n\nRecent 24-hour ambulatory blood pressure monitoring (ABPM) (\\\u003C1 month) showing values above target (24-hour BP ≥130\u002F80 mmHg);\n\nOffice blood pressure ≥140\u002F90 mmHg;\n\nPoor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4).\n\n\\-\n\nExclusion Criteria:Secondary hypertension (including hyperaldosteronism, pheochromocytoma, or renovascular hypertension);\n\nHistory of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache);\n\nIndispensable use of beta-blockers or mineralocorticoid receptor antagonists;\n\nOffice blood pressure ≥ 220 × 120 mmHg;\n\nReduced left ventricular ejection fraction (LVEF \\\u003C 55%);\n\nSevere renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²);\n\nAtrial fibrillation or atrial flutter;\n\nUse of oral anticoagulants;\n\nSignificant valvular heart disease;\n\nBody mass index (BMI) ≥ 40 kg\u002Fm²;\n\nPregnant or breastfeeding women;\n\nSevere psychiatric disorders;\n\nActive malignancy with life expectancy \\\u003C 2 years;\n\n\\-","75 Years",{"count":430,"type":20},142,[107],"This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.",[434,83,25],"Apparent Resistant Hypertension",[436],"Apparent resistant hypertension; Fixed-dose combination; Triple combination therapy; Perindoprile; Indapamide; Amlodipine; Clinical Trial; Brazil","2025-11-21",{"date":411,"type":30},{"date":440,"type":30},"2023-07-15",{"date":442,"type":20},"2026-12-31",{"name":444,"class":37},"Instituto Dante Pazzanese de Cardiologia",{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":47,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":467},"100463951","a-cardiometabolic-health-program-linked-with-clinical-community-support-and-mobile-health-telemonitoring-to-reduce-health-disparities-100463951","NCT05321368","A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities","LINKED-HEARTS","Inclusion Criteria:\n\n1. 18 years of age as of date of data extraction,\n2. Self-identify as non-Hispanic white, non-Hispanic Black\u002FAfrican American and\u002For Hispanic,\n3. Diagnosis of Hypertension (HTN) defined by International Classification of Diseases, Tenth code (ICD-10 code) and elevated systolic blood pressure (SBP) measure (≥140 mm Hg) on their most recent clinic visit.\n4. Diagnosis of diabetes or chronic kidney disease (both defined by ICD-10 code), in addition to HTN\n5. Receives primary medical care at one of the participating health systems\n6. Have a Maryland and D.C. home address\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Diagnosis of end-stage renal disease (ESRD) treated with dialysis\n3. Serious medical condition which either limits life expectancy or requires active management (e.g., cancer)\n4. Cognitive impairment or other condition preventing participation in the intervention\n5. Planning to leave the practice or move out of the geographic area in 24 months\n6. No longer consider the practice site their location for primary care\n7. Unwillingness to provide informed consent",{"count":453,"type":20},425,[107],"The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hypertension (BP ≥ 140\u002F90 mm Hg) AND either type 2 diabetes or chronic kidney disease (CKD) across 16 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced \"usual care arm,\" wherein patients will be provided with Omron 10 series home BP monitors and will be managed by the patients' primary care clinicians as usual; and (2) the \"intervention arm\" which will integrate HBPM telemonitoring, a CHW intervention and provider-level interventions into the usual clinical care to improve BP control and provide support for self-management of chronic conditions. The study pharmacist will conduct telehealth, use the Sphygmo app and the Pharmacist Patient Care Process to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.",[83,25,457,458],"Diabetes","Chronic Kidney Diseases","2025-10-07",{"date":461,"type":30},"2025-10-09",{"date":463,"type":30},"2023-10-16",{"date":465,"type":20},"2027-04-22",{"name":367,"class":37},3,{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":47,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":38},"100527653","phase-3-a-study-of-angiotensin-ii-receptor-blocker-on-cardiovascular-remodeling-value-trial-100527653","NCT06150560","A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta","VALUE","Inclusion Criteria:\n\n* B\u002FS1 hypertension\n* SBP 100-139 average based on 3 office measurements.\n* Age 18 or Older\n* Previous COA Repair\n\nExclusion Criteria:\n\n* Currently on beta blocker (BB) therapy\n* Pregnancy\u002Flactating\n* eGFR\\\u003C30\n* Hyperkalemia (serum potassium \\>5.5mmol\u002FL)\n* Severe Aortic or Mitral valve stenosis or regurgitation\n* Epicardial CAD diagnosis\n* Received antihypertensive medications within the past year",{"count":477,"type":20},120,[296],"The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.",[481,25],"Coarctation of Aorta","2025-07-30",{"date":484,"type":30},"2025-08-03",{"date":486,"type":30},"2024-04-01",{"date":488,"type":20},"2028-06-01",{"name":490,"class":37},"Mayo Clinic",{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":47,"phases":499,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":512,"locationsCount":38},"100561694","addressing-cardiometabolic-health-in-populations-through-early-prevention-in-the-great-lakes-region-project-1---epidemiology-achieve-p1-epi-100561694","NCT06593496","Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region Project 1 - Epidemiology (ACHIEVE P1-EPI)","Inclusion Criteria:\n\n* Mobile Health Unit Patients with blood pressure above normal (≥120 systolic and\u002For ≥80 mmHg)\n* Has a phone with the ability to receive text messages\n* 18+ years old\n* Consent to allow prospective follow-up including through EHR review\n\nExclusion Criteria:\n\n* Non-mobile health unit patients\n* MHU patients with systolic BP \\\u003C 120 mmHg AND diastolic BP \\\u003C 80 mmHg\n* Pregnant Women\n* Children less than 18 years old\n* Individuals viewed by the investigative team as unable to understand and sign the informed consent form\n* Currently enrolled in another on-going interventional trial initiated on the mobile health unit",{"count":498,"type":20},1000,[107],"This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland.\n\nThe present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).",[83,25],[503,504,505],"Epidemiology","Mobile Health Unit","Prospective","2025-07-09",{"date":508,"type":30},"2025-07-15",{"date":510,"type":30},"2025-06-11",{"date":488,"type":20},{"name":513,"class":37},"Wayne State University",{"id":515,"slug":516,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":47,"phases":524,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":38},"100527115","phase-1-polypill-for-prevention-of-cardiomyopathy-100527115","NCT06143566","Polypill for Prevention of Cardiomyopathy","Polypill Strategy for Prevention of Cardiomyopathy Among Patients With Diabetes at Risk of Heart Failure","PolyPreventHF","Inclusion Criteria:\n\n* Patients with Type 2 DM\n* History of chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) of 25 to 90 per minute per 1.73 m2 of body-surface area (stage 2 to 4 CKD) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of less than 5000\n* With either a: High risk of HF as defined by High Watch-DM score (≥11) or Elevated natriuretic peptides or Diastolic dysfunction or left ventricular hypertrophy on echocardiography\n\nExclusion Criteria:\n\n* eGFR \\\u003C 25\n* Congestive heart failure\n* Hyperkalemia \\> 5.0\n* Contraindication to any component of polypill\n* Pregnancy\n* Creatinine \\>2.0mg\u002FdL in men and \\>1.8mg\u002FdL in women\n* Inability to calculate WATCH-DM score\n* Inability to undergo exercise testing","100 Years",{"count":239,"type":20},[182,49],"This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or simultaneous prescription of the individual drugs. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypothesize that the use of a polypill is feasible and improves medication adherence and peak VO2 as compared to those receiving usual care.",[527,25],"Type 2 Diabetes",[527,529,83,530],"Diabetic Cardiomyopathy","Polypill","2025-06-12",{"date":533,"type":30},"2025-06-17",{"date":535,"type":30},"2024-03-11",{"date":537,"type":20},"2027-12-01",{"name":539,"class":37},"University of Texas Southwestern Medical Center",{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":47,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":284},"100553557","cardiocare-quest-a-co-created-game-for-improving-hypertension-treatment-compliance-in-arizona-100553557","NCT06487637","CardioCare Quest: A Co-created Game for Improving Hypertension Treatment Compliance in Arizona","Inclusion Criteria:\n\n* We are interested in interviewing people who receive, give, or are affected by HBP therapy. This includes medical professionals, patients with HBP between the ages of 18 and above, their family members, caretakers, and relevant community professionals such as social workers.\n* The project targets Urban Indigenous individuals in the patient category. A potential participant will be recognized as Urban Indigenous upon completing the registration form provided to them.\n* The project is interested in Navajo Nation groups that reside in Flagstaff.\n\nExclusion Criteria:\n\n* Patients with uncontrolled or severely severe hypertension will be excluded from this study since controlling these instances may be the primary emphasis of the study rather than its intervention.\n* The exclusion will be based on considerations such as the severity of hypertension, the potential risks associated with uncontrolled hypertension, and the overall health status of the patient.\n* Participants having specific medical conditions that could interfere with or pose risks to the study's outcomes (e.g., severe heart disease, advanced kidney disease) will be excluded.\n* Pregnant women or those who want to get pregnant during the study period will be excluded due to the potential dangers to both the pregnant woman and the fetus.",{"count":547,"type":20},60,[107],"This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.",[25],[115,552,553,554,555],"Co design","Game and play","Telemetry data","diet and exercise","2025-06-02",{"date":558,"type":30},"2025-06-05",{"date":560,"type":30},"2024-06-30",{"date":562,"type":20},"2026-11-01",{"name":564,"class":37},"Northern Arizona University",{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":178,"enrollmentInfo":573,"targetDuration":4,"studyType":47,"phases":575,"briefSummary":576,"conditions":577,"keywords":580,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":38},"100338454","phase-1-evaluation-of-superiority-of-valsartancelecoxibmetformin-over-metformin-alone-in-type-2-diabetes-patients-100338454","NCT03686657","Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients","RESILIENCE","Inclusion Criteria:\n\n1. Males and females, Age: \\>18 to 70 years at the time of screening visit.\n2. Women of childbearing potential (WOCBP) must have negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent of HCG) within 24 hours prior to the start of the study.\n3. Women must not be breastfeeding.\n4. HbA1c≥8.0\n5. Patients with inadequate blood glucose control with Metformin defined as a central laboratory glycosylated hemoglobin (HbA1c) \\>8.0 and \\\u003C10.5 obtained at the screening visit. Metformin-HCl monotherapy was inadequate 3 months prior to the study as indicated by the lack of decrease and\u002For an increase in the A1c level.\n\n   Newly diagnosed drug naïve patients as defined by HbA1c\\>7.0 at the screening visit. Drug naïve subjects diagnosed with type 2 diabetes within 6 months of diagnosis will be considered and selected.\n\n   About half the patients are expected to be newly diagnosed in the study.\n6. Drug naive as well as osteoarthritis patients with Type 2 diabetes receiving a non-aspirin pain reliever (e.g. acetaminophen) or an NSAID (e.g. Naproxen).\n7. Max\u002Fmaintenance dose Metformin. Subjects should have been taking the same daily dose of metformin for at least 8 weeks prior to the enrollment visit and subjects not receive these other antihyperglycemic medications within the 12 weeks prior to screening (except for short-term use of insulin \\[≤7 days\\] during concomitant illness or other stress).\n8. Patients with \\>25% AIRg at 2 minutes and 10 minutes.\n9. RAS blocker naïve patients\n10. 2-Hour OGTT ≥200 mg\u002FdL\n11. FPG ≥140 mg\u002FdL\n12. BMI ≥30\n13. Impaired first phase and second phase of insulin secretion\n14. BP ≥140\u002F90 mm Hg (These patients might be on an anti-hypertensive drug)\n15. Non-fasting laboratory glucose \\>200 mg\u002FdL with symptoms of polydipsia, polyuria and\u002For Polyphagia\n16. eGFR ≥ 60 ml\u002Fmin\u002F1.73m2\n\nExclusion Criteria:\n\n1. Age \\>70\n2. Patients with Type 1 diabetes, Screen for GAD (Glutamic acid decarboxylase) antibodies at the time of screening visit. To rule out latent autoimmune diabetes in adults (LADA), screening for other diabetes-related antibodies, such as insulinoma-associated protein (IA-2 and IA-2 beta), zinc transporter-8 (ZnT8), islet cell antibodies (ICA) or insulin autoantibody (IAA) will also be considered.\n3. Pregnant women\n4. Patients with a history of Ketoacidosis.\n5. Subjects at serious risk of gastrointestinal (GI) adverse events (e.g. current or recent history of GI bleeding ulceration, or perforation).\n6. Subjects with a planned radiologic study with intravenous contrast, surgery, or other planned procedures that may predispose them to metformin-associated lactic acidosis.\n7. Insulin dependent: \\\u003C25% Beta-cell function: AIRg (Acute insulin response to glucose after 2 min and 10 min after glucose injection) INSULIN DEPENDENT STATE.\n8. Patients with a history of uncontrolled hyperglycemia \\>15.0 mmol\u002FL (280 mg\u002FdL) after an overnight fast that required rescue therapy.\n9. Patients with uncontrolled hyperglycemia \\>15.0 mmol\u002FL (280 mg\u002FdL) after an overnight fast that required rescue therapy during week 1-3 Metformin-HCl monotherapy or RK-01 therapy.\n10. eGFR, impaired kidney function \\\u003C 60 ml\u002Fmin\u002F1.73m2.\n11. Poor metabolizers of Cyp450 2C9 to avoid very high concentration (Since Cytochrome 450 2C9 is responsible for the metabolism of both Valsartan and Celecoxib, patients who are known or suspected to be poor Cyp450 2C9 metabolizers based on previous history will be excluded from the study).\n12. Any of the following cardiovascular (CV)\u002FVascular diseases within 3 months of the enrollment visit:\n\n    1. Myocardial infarction (MI)\n    2. Cardiac surgery or revascularization (coronary artery bypass surgery, Coronary Artery Bypass Graft \\[(CABG\\]\u002FPercutaneous transluminal coronary angioplasty (PTCA)\\].\n    3. Unstable angina\n    4. Unstable congestive heart failure (CHF)\n    5. Transient ischemic attack (TIA) or significant cerebrovascular disease\n    6. Unstable or previously diagnosed arrhythmia\n    7. Congestive heart failure, defined as New York Heart Association (NYHA) Class III and IV, unstable or acute heart failure and\u002For known left ventricular ejection fraction of ≤40%.\n    8. Acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to the informed consent.\n13. Previous bariatric surgery\n14. Treatment with anti-obesity drugs within 3 months prior to consent\n15. Patients with COPD\n16. Patients with liver disease\n17. Patients with renal disease\n18. Patients with autoimmune diseases e.g. Lupus, Psoriasis\n19. Patients with HIV\u002FAIDS\n20. Patients with diabetes-related complications\n21. Patients with Hematological and Oncological Diseases\u002FConditions\n22. Hemoglobin \\\u003C11.0 g\u002FdL (110 g\u002FL) for men; hemoglobin \\\u003C10.0 g\u002FdL (100 g\u002FL) for women\n23. Patients with chronic disease e.g. Cancer, Epilepsy, Alzheimer, Parkinson, Asthma\n24. Abnormal free T4\n25. Patients with serious infection",{"count":574,"type":20},115,[182,49],"Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure, arthritis and inadequate glycemic control with metformin monotherapy, diet and exercise over 26 weeks of treatment.\n\nObjective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy.\n\nHypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.",[527,25,578,579],"Arthritis","Obesity",[457,579,581,582,583,584],"FPG","Beta cell function index","HbA1c","Atherogenic index","2025-05-29",{"date":587,"type":30},"2025-06-03",{"date":589,"type":20},"2025-10-10",{"date":591,"type":20},"2029-01-31",{"name":593,"class":93},"ARKAY Therapeutics",{"id":595,"slug":596,"hasResults":11,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":600,"phases":4,"briefSummary":601,"conditions":602,"keywords":604,"overallStatus":610,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":614,"locationsCount":38},"100534631","chronic-effect-of-mat-pilates-on-neuromotor-cardiovascular-functions-and-inflammatory-markers-in-individuals-post-stroke-stroke-and-high-blood-pressure-100534631","NCT06241339","Chronic Effect of Mat Pilates on Neuromotor, Cardiovascular Functions and Inflammatory Markers in Individuals Post-Stroke Stroke and High Blood Pressure","Inclusion Criteria: Hemiparetic individuals with a history of stroke and\u002For high blood pressure (prehypertensive and hypertensive patients) who are controlled and do not practice the Pilates method.\n\nExclusion Criteria: Diagnosis of cardiovascular, respiratory, metabolic or locomotor disease that makes it impossible or contraindicates the practice of the proposed exercises; Uncontrolled hypertension (systolic BP ≥160 mmHg or diastolic pressure and ≥105 mmHg at rest); Spasticity: 3 according to the modified Ashworth Scale; Smoking and frequencies in exercise sessions below 75%.","EXPANDED_ACCESS","The Pilates method aims to develop conscious control of body movements. In the literature there are studies that relate the method to postural stabilization, joint rehabilitation, treatment of low back pain, cancer and chronic obstructive pulmonary disease. However, studies on the modality\\'s potential for improving isokinetic and antihypertensive strength are scarce, particularly in post-stroke hemiparetic individuals with high blood pressure (BP). The objective of the study is to investigate changes in isokinetic strength and BP, in addition to functional capacity, balance, autonomic modulation, blood biomarkers and endothelial function in hemiparetic individuals due to stroke sequelae and\u002For with high BP (prehypertensive and hypertensive), after 12 weeks of training with Mat Pilates. Eligible volunteers will be randomly divided into a Mat Pilates group with stroke (GP-AVE), Mat Pilates group with high blood pressure (HA) (GP-HA), control group with stroke (GC-AVE) and control group with HA (GC-HA ). On the first and second visit, measurements of isokinetic strength, functional capacity, static and dynamic balance, heart rate variability, cardiac output, stroke volume, endothelial function, total peripheral vascular resistance and blood biomarkers will be carried out. In addition, 24-hour BP will be measured by ambulatory monitoring (ABPM). GP-AVE and GP-HA will participate in a 12-week Mat Pilates program, totaling 36 training sessions lasting approximately 60 minutes, with an increasing degree of difficulty and complexity throughout the training period. GC-AVE and GC-HA will be instructed to maintain their daily activities during the intervention period, then they will be invited to participate in the Mat Pilates program. The initial measurements will be repeated at the end of the intervention in the Mat Pilates and control groups. Intra and intergroup comparisons will be carried out for all outcomes, for a significance level set at p ≤ 0.05.",[603,25],"Stroke",[605,606,607,608,609],"Autonomy","hemodynamic","balance","muscle strength","chronic reduction in blood pressure","AVAILABLE","2025-04-01",{"date":613,"type":30},"2025-04-03",{"name":615,"class":37},"Rio de Janeiro State University"]